Cargando…
A combination of two ELISA tests for nasopharyngeal carcinoma screening in endemic areas based on a case-control study
For populations with a high risk of nasopharyngeal carcinoma (NPC) in Guangdong province in southern China, mass screening is the first choice to prevent death from NPC. To improve the performance of NPC screening, we used a combination based on the IgA antibody against the Epstein-Barr virus (EBV)...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PeerJ Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666820/ https://www.ncbi.nlm.nih.gov/pubmed/33240616 http://dx.doi.org/10.7717/peerj.10254 |
_version_ | 1783610207009505280 |
---|---|
author | Rao, Dongping Fu, Meiqin Chen, Yingjie Liu, Qing Xiao, Lin Zhang, Xin Li, Zhongxiao Li, Haitao He, Yongyi Chen, Yongxing Chen, Jieying Hu, Jin Huang, Yanming |
author_facet | Rao, Dongping Fu, Meiqin Chen, Yingjie Liu, Qing Xiao, Lin Zhang, Xin Li, Zhongxiao Li, Haitao He, Yongyi Chen, Yongxing Chen, Jieying Hu, Jin Huang, Yanming |
author_sort | Rao, Dongping |
collection | PubMed |
description | For populations with a high risk of nasopharyngeal carcinoma (NPC) in Guangdong province in southern China, mass screening is the first choice to prevent death from NPC. To improve the performance of NPC screening, we used a combination based on the IgA antibody against the Epstein-Barr virus (EBV) capsid antigen (VCA-IgA) and the IgA antibody against Epstein-Barr virus nuclear antigen 1 (EBNA1-IgA) to NPC screening by enzyme-linked immunosorbent assay (ELISA). A multiplication model was applied to measure the level of the combination. We evaluated the NPC screening effect of the markers.A case-control study was performed to assess the NPC screening effect of the markers. A total of 10,894 serum specimens were collected, including 554 samples from NPC patients and 10,340 samples from healthy controls. In the training stage, 640 subjects were randomly selected, including 320 NPC cases and 320 healthy controls. In the verification stage, 10,254 subjects were used to verify the NPC screening effect of the combination. Receiver operating characteristic (ROC) analysis was performed. In the verification stage, the combination achieved an sensitivity of 91.45%, a specificity of 93.45%, and an area under the ROC curve (AUC) of 0.978 (95% CI [0.968–0.987]). Compared with VCA-IgA and EBNA1-IgA individually, the combination had an improved screening performance. A probability (PROB) calculated by logistic regression model based on VCA-IgA and EBNA1-IgA was applied to NPC screening by ELISA in China. The AUC of the combination was a little bit larger than the PROB. There was a slight increase (3.13%) in the sensitivity of the combination compared to the sensitivity of the PROB, while the specificity was lower for the combination (92.50%) than for the PROB (95.94%). We successfully applied a combination of two ELISA tests based on VCA-IgA and EBNA1-IgA for NPC screening by using a multiplication model. The results suggested that the combination was effective and can be an option for NPC screening. |
format | Online Article Text |
id | pubmed-7666820 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | PeerJ Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-76668202020-11-24 A combination of two ELISA tests for nasopharyngeal carcinoma screening in endemic areas based on a case-control study Rao, Dongping Fu, Meiqin Chen, Yingjie Liu, Qing Xiao, Lin Zhang, Xin Li, Zhongxiao Li, Haitao He, Yongyi Chen, Yongxing Chen, Jieying Hu, Jin Huang, Yanming PeerJ Epidemiology For populations with a high risk of nasopharyngeal carcinoma (NPC) in Guangdong province in southern China, mass screening is the first choice to prevent death from NPC. To improve the performance of NPC screening, we used a combination based on the IgA antibody against the Epstein-Barr virus (EBV) capsid antigen (VCA-IgA) and the IgA antibody against Epstein-Barr virus nuclear antigen 1 (EBNA1-IgA) to NPC screening by enzyme-linked immunosorbent assay (ELISA). A multiplication model was applied to measure the level of the combination. We evaluated the NPC screening effect of the markers.A case-control study was performed to assess the NPC screening effect of the markers. A total of 10,894 serum specimens were collected, including 554 samples from NPC patients and 10,340 samples from healthy controls. In the training stage, 640 subjects were randomly selected, including 320 NPC cases and 320 healthy controls. In the verification stage, 10,254 subjects were used to verify the NPC screening effect of the combination. Receiver operating characteristic (ROC) analysis was performed. In the verification stage, the combination achieved an sensitivity of 91.45%, a specificity of 93.45%, and an area under the ROC curve (AUC) of 0.978 (95% CI [0.968–0.987]). Compared with VCA-IgA and EBNA1-IgA individually, the combination had an improved screening performance. A probability (PROB) calculated by logistic regression model based on VCA-IgA and EBNA1-IgA was applied to NPC screening by ELISA in China. The AUC of the combination was a little bit larger than the PROB. There was a slight increase (3.13%) in the sensitivity of the combination compared to the sensitivity of the PROB, while the specificity was lower for the combination (92.50%) than for the PROB (95.94%). We successfully applied a combination of two ELISA tests based on VCA-IgA and EBNA1-IgA for NPC screening by using a multiplication model. The results suggested that the combination was effective and can be an option for NPC screening. PeerJ Inc. 2020-11-12 /pmc/articles/PMC7666820/ /pubmed/33240616 http://dx.doi.org/10.7717/peerj.10254 Text en ©2020 Rao et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited. |
spellingShingle | Epidemiology Rao, Dongping Fu, Meiqin Chen, Yingjie Liu, Qing Xiao, Lin Zhang, Xin Li, Zhongxiao Li, Haitao He, Yongyi Chen, Yongxing Chen, Jieying Hu, Jin Huang, Yanming A combination of two ELISA tests for nasopharyngeal carcinoma screening in endemic areas based on a case-control study |
title | A combination of two ELISA tests for nasopharyngeal carcinoma screening in endemic areas based on a case-control study |
title_full | A combination of two ELISA tests for nasopharyngeal carcinoma screening in endemic areas based on a case-control study |
title_fullStr | A combination of two ELISA tests for nasopharyngeal carcinoma screening in endemic areas based on a case-control study |
title_full_unstemmed | A combination of two ELISA tests for nasopharyngeal carcinoma screening in endemic areas based on a case-control study |
title_short | A combination of two ELISA tests for nasopharyngeal carcinoma screening in endemic areas based on a case-control study |
title_sort | combination of two elisa tests for nasopharyngeal carcinoma screening in endemic areas based on a case-control study |
topic | Epidemiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666820/ https://www.ncbi.nlm.nih.gov/pubmed/33240616 http://dx.doi.org/10.7717/peerj.10254 |
work_keys_str_mv | AT raodongping acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT fumeiqin acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT chenyingjie acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT liuqing acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT xiaolin acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT zhangxin acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT lizhongxiao acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT lihaitao acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT heyongyi acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT chenyongxing acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT chenjieying acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT hujin acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT huangyanming acombinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT raodongping combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT fumeiqin combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT chenyingjie combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT liuqing combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT xiaolin combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT zhangxin combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT lizhongxiao combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT lihaitao combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT heyongyi combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT chenyongxing combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT chenjieying combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT hujin combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy AT huangyanming combinationoftwoelisatestsfornasopharyngealcarcinomascreeninginendemicareasbasedonacasecontrolstudy |